거대 세포 동맥염 시장 규모는 향후 수년간 안정적인 성장을 보일 것으로 예상되며, 2029년에는 13억 6,000만 달러에 달할 것으로 예상되며, 연평균 5.0%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 예측 기간의 성장은 진단율 증가, 고령화, 의료비 지출 증가, 환자 지지, 새로운 지역으로의 확장 등에 기인합니다. 예측 기간 중 주요 동향으로는 바이오마커 식별 및 검증의 발전, 특정 분자 경로를 표적으로 하는 치료법 개발, 첨단 이미징 기술 채택, 약물전달의 혁신, 예측 분석을 위한 AI 알고리즘 활용 등이 있습니다.
맞춤의료에 대한 관심이 높아지면서 향후 수년간 거대세포 동맥염 시장의 성장을 가속할 것으로 예상됩니다. 맞춤의료는 유전, 생활습관, 환경적 요인 등 개인의 특성에 맞게 치료를 조정하는 것을 포함합니다. 이러한 접근법은 유전체학, 생명공학, 데이터 분석의 발전으로 인해 치료 효과를 높이고 환자의 부작용을 최소화하며 보다 정확한 치료를 가능하게 함으로써 추진력을 얻고 있습니다. 거대세포 동맥염(GCA)의 맥락에서 맞춤형 의료는 유전적 소인, 면역 반응, 특정 질병 증상과 같은 요인에 기반한 표적 치료로 이어집니다. 예를 들어 2024년 2월 개인맞춤의료연합(PMC)에 따르면 2023년 미국 식품의약국(FDA)이 승인한 신약의 3분의 1 이상이 개인맞춤형 의약품이었다고 합니다. 이는 4년 연속 큰 폭으로 증가한 것으로, 2022년에 6건이 승인된 것에 비해 16건의 희귀질환을 위한 맞춤형 치료제가 승인되었습니다. 이러한 승인에는 암 및 기타 질환에 대한 치료제가 포함되어 있으며, 헬스케어 분야에서 개인맞춤형 접근법의 채택이 증가하고 있으며, GCA와 같은 질환 관리에 미치는 영향을 강조하고 있습니다.
거대세포성 동맥염 시장의 주요 기업은 치료 옵션을 넓히고 환자들의 니즈를 충족시키기 위해 바이오시밀러와 같은 신제품을 출시하고 있습니다. 바이오시밀러는 승인된 생물제제와 매우 유사한 생물제제로 안전성, 순도, 역가 등에서 임상적으로 의미 있는 차이가 없음을 보장하는 생물제제입니다. 예를 들어 2024년 4월 Fresenius SE &Co.KGaA는 류마티스 관절염(RA), 전신형 청년 특발성 관절염(JIA), 다관절형 청년 특발성 관절염(PJIA), 거대세포성 동맥염을 포함한 만성 자가면역질환에 대한 바이오시밀러를 승인받았습니다. Tocilizumab-aazg를 2024년 4월 미국에서 출시했습니다. 이번 승인은 토실리주맙의 약동학, 안전성, 면역원성을 참조 토실리주맙 제제와 비교한 임상 1상 시험의 종합적인 평가에 기반한 것입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 거대 세포성 동맥염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 거대 세포성 동맥염 시장 : 성장률 분석
- 세계의 거대 세포성 동맥염 시장 실적 : 규모와 성장, 2019-2024
- 세계의 거대 세포성 동맥염 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 거대 세포성 동맥염 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 거대 세포성 동맥염 시장 : 치료법별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- Prednisone
- Methotrexate
- Tocilizumab
- 아스피린
- 세계의 거대 세포성 동맥염 시장 : 작용기서별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 코르티코스테로이드
- 면역억제제
- 항응고제
- 기타 작용기서
- 세계의 거대 세포성 동맥염 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 정맥내
- 피하
- 기타 투여 경로
- 세계의 거대 세포성 동맥염 시장, Prednisone의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 Prednisone
- 정맥내(IV) Prednisone
- 저용량 Prednisone 요법
- 고용량 Prednisone 요법
- 세계의 거대 세포성 동맥염 시장, Methotrexate의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 Methotrexate
- 피하 Methotrexate
- Methotrexate 단독요법
- Methotrexate 병용요법
- 세계의 거대 세포성 동맥염 시장, Tocilizumab의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 정맥내 Tocilizumab
- 피하 Tocilizumab
- Tocilizumab 단독요법
- Tocilizumab와 코르티코스테로이드 병용
- 세계의 거대 세포성 동맥염 시장, 아스피린의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 저용량 아스피린 요법
- 심혈관 리스크 관리를 위한 아스피린
- 아스피린 병용요법
- 장용성 아스피린
제7장 지역별·국가별 분석
- 세계의 거대 세포성 동맥염 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 거대 세포성 동맥염 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 거대 세포성 동맥염 시장 : 경쟁 구도
- 거대 세포성 동맥염 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Bayer AG
- Sanofi SA
- Bristol-Myers Squibb Company
- Novartis AG
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Boehringer Ingelheim
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CSL Limited
- Kiniksa Pharmaceuticals Ltd.
- MorphoSys AG
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 거대 세포성 동맥염 시장 2029 : 새로운 기회를 제공하는 국가
- 거대 세포성 동맥염 시장 2029 : 새로운 기회를 제공하는 부문
- 거대 세포성 동맥염 시장 2029 : 성장 전략
제36장 부록
KSA
Giant-cell arteritis (GCA) is a form of vasculitis, characterized by inflammation of medium to large arteries. It often affects the temporal arteries, causing symptoms such as headaches, scalp tenderness, and vision issues. If untreated, GCA can lead to severe complications such as blindness or stroke due to inflammation of vessel walls. Treatment typically involves high doses of corticosteroids to reduce inflammation and prevent complications.
Common therapeutics for giant-cell arteritis include prednisone, methotrexate, tocilizumab, and aspirin. Prednisone, a corticosteroid, works by suppressing inflammation and immune responses. It is administered via various routes such as oral, intravenous, and subcutaneous, and is utilized for its anti-inflammatory, immunosuppressive, and anticoagulant properties.
The giant-cell arteritis market research report is one of a series of new reports from The Business Research Company that provides giant-cell arteritis market statistics, including giant-cell arteritis industry global market size, regional shares, competitors with a giant-cell arteritis market share, detailed giant-cell arteritis market segments, market trends and opportunities, and any further data you may need to thrive in the giant-cell arteritis industry. This giant-cell arteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The giant-cell arteritis market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to epidemiological studies, genetic insights, increasing adoption of biologics, improving diagnostic techniques, and development of targeted therapies and biologics.
The giant-cell arteritis market size is expected to see steady growth in the next few years. It will grow to $1.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing diagnosis rates, aging population, rising healthcare expenditure, patient advocacy, expansion into new geographic regions. Major trends in the forecast period include advancements in identifying and validating biomarkers, development of therapies targeting specific molecular pathways, adoption of advanced imaging techniques, drug delivery innovations, utilization of AI algorithms for predictive analytics.
The increasing focus on personalized medicine is expected to drive growth in the giant-cell arteritis market in the coming years. Personalized medicine involves tailoring medical treatments to individual characteristics such as genetics, lifestyle, and environmental factors. This approach is gaining momentum due to advancements in genomics, biotechnology, and data analytics, which enable more precise therapies that enhance treatment effectiveness and minimize side effects for patients. In the context of giant-cell arteritis (GCA), personalized medicine can lead to targeted therapies based on factors such as genetic predispositions, immune responses, and specific disease symptoms. For example, according to the Personalized Medicine Coalition (PMC) in February 2024, over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2023 were for personalized medicines. This marked the fourth consecutive year of significant growth, with 16 new treatments tailored for rare diseases approved, compared to six approvals in 2022. These approvals included medications for cancer and other conditions, underscoring the increasing adoption of personalized approaches in healthcare and their impact on disease management such as GCA.
Leading companies in the giant-cell arteritis market are advancing by introducing new products such as biosimilars to expand treatment options and meet patient needs. Biosimilars are biologic drugs highly similar to approved biological products, ensuring no clinically meaningful differences in safety, purity, and potency. For instance, in April 2024, Fresenius SE & Co. KGaA launched Tocilizumab-aazg in the U.S., a biosimilar approved for chronic autoimmune diseases including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval followed a comprehensive evaluation in a phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity to reference tocilizumab products.
In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired Teva's manufacturing facility in Goa, India, enhancing its production capacity significantly. This acquisition doubles Marksans Pharma's manufacturing capabilities in India, enabling the production of various pharmaceutical products including tablets, capsules, ointments, liquids, and creams. Teva Pharmaceutical, based in Israel, is known for its contributions in producing medications such as prednisone tablets used in the treatment of giant-cell arteritis.
Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG
North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the giant-cell arteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The giant-cell arteritis market consists of revenues earned by entities by services such as monitoring and follow-up, supportive care, diagnostic testing, treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The giant-cell arteritis market also includes sales of biologics, diagnostic tools, biopsy kits and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Giant-Cell Arteritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on giant-cell arteritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for giant-cell arteritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The giant-cell arteritis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin
- 2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action
- 3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration
- Subsegments:
- 1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy
- 2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy
- 3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids
- 4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Giant-Cell Arteritis Market Characteristics
3. Giant-Cell Arteritis Market Trends And Strategies
4. Giant-Cell Arteritis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Giant-Cell Arteritis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Giant-Cell Arteritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Giant-Cell Arteritis Market Growth Rate Analysis
- 5.4. Global Giant-Cell Arteritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Giant-Cell Arteritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Giant-Cell Arteritis Total Addressable Market (TAM)
6. Giant-Cell Arteritis Market Segmentation
- 6.1. Global Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prednisone
- Methotrexate
- Tocilizumab
- Aspirin
- 6.2. Global Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Corticosteroids
- Immunosuppressive Agents
- Anticoagulants
- Other Mechanisms Of Action
- 6.3. Global Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous
- Subcutaneous
- Other Routes Of Administration
- 6.4. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Prednisone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Prednisone
- Intravenous (IV) Prednisone
- Low-Dose Prednisone Therapy
- High-Dose Prednisone Therapy
- 6.5. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Methotrexate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Methotrexate
- Subcutaneous Methotrexate
- Methotrexate Monotherapy
- Methotrexate Combination Therapy
- 6.6. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Tocilizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous Tocilizumab
- Subcutaneous Tocilizumab
- Tocilizumab Monotherapy
- Tocilizumab In Combination With Corticosteroids
- 6.7. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Low-Dose Aspirin Therapy
- Aspirin For Cardiovascular Risk Management
- Aspirin In Combination Therapy
- Enteric-Coated Aspirin
7. Giant-Cell Arteritis Market Regional And Country Analysis
- 7.1. Global Giant-Cell Arteritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Giant-Cell Arteritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Giant-Cell Arteritis Market
- 8.1. Asia-Pacific Giant-Cell Arteritis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Giant-Cell Arteritis Market
- 9.1. China Giant-Cell Arteritis Market Overview
- 9.2. China Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Giant-Cell Arteritis Market
- 10.1. India Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Giant-Cell Arteritis Market
- 11.1. Japan Giant-Cell Arteritis Market Overview
- 11.2. Japan Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Giant-Cell Arteritis Market
- 12.1. Australia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Giant-Cell Arteritis Market
- 13.1. Indonesia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Giant-Cell Arteritis Market
- 14.1. South Korea Giant-Cell Arteritis Market Overview
- 14.2. South Korea Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Giant-Cell Arteritis Market
- 15.1. Western Europe Giant-Cell Arteritis Market Overview
- 15.2. Western Europe Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Giant-Cell Arteritis Market
- 16.1. UK Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Giant-Cell Arteritis Market
- 17.1. Germany Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Giant-Cell Arteritis Market
- 18.1. France Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Giant-Cell Arteritis Market
- 19.1. Italy Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Giant-Cell Arteritis Market
- 20.1. Spain Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Giant-Cell Arteritis Market
- 21.1. Eastern Europe Giant-Cell Arteritis Market Overview
- 21.2. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Giant-Cell Arteritis Market
- 22.1. Russia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Giant-Cell Arteritis Market
- 23.1. North America Giant-Cell Arteritis Market Overview
- 23.2. North America Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Giant-Cell Arteritis Market
- 24.1. USA Giant-Cell Arteritis Market Overview
- 24.2. USA Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Giant-Cell Arteritis Market
- 25.1. Canada Giant-Cell Arteritis Market Overview
- 25.2. Canada Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Giant-Cell Arteritis Market
- 26.1. South America Giant-Cell Arteritis Market Overview
- 26.2. South America Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Giant-Cell Arteritis Market
- 27.1. Brazil Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Giant-Cell Arteritis Market
- 28.1. Middle East Giant-Cell Arteritis Market Overview
- 28.2. Middle East Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Giant-Cell Arteritis Market
- 29.1. Africa Giant-Cell Arteritis Market Overview
- 29.2. Africa Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Giant-Cell Arteritis Market Competitive Landscape And Company Profiles
- 30.1. Giant-Cell Arteritis Market Competitive Landscape
- 30.2. Giant-Cell Arteritis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Giant-Cell Arteritis Market Other Major And Innovative Companies
- 31.1. Bayer AG
- 31.2. Sanofi SA
- 31.3. Bristol-Myers Squibb Company
- 31.4. Novartis AG
- 31.5. GlaxoSmithKline Plc
- 31.6. Takeda Pharmaceutical Company Limited
- 31.7. Eli Lilly and Company
- 31.8. Amgen Inc.
- 31.9. Boehringer Ingelheim
- 31.10. Teva Pharmaceutical Industries Ltd.
- 31.11. Regeneron Pharmaceuticals Inc.
- 31.12. Astellas Pharma Inc.
- 31.13. CSL Limited
- 31.14. Kiniksa Pharmaceuticals Ltd.
- 31.15. MorphoSys AG
32. Global Giant-Cell Arteritis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Giant-Cell Arteritis Market
34. Recent Developments In The Giant-Cell Arteritis Market
35. Giant-Cell Arteritis Market High Potential Countries, Segments and Strategies
- 35.1 Giant-Cell Arteritis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Giant-Cell Arteritis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Giant-Cell Arteritis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
